A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a previous pilot study, adrenal suppression was found to be common after antiemetic dexamethasone therapy in cancer patients. The objective of this large prospective multicenter study was to confirm the incidence and factors associated with secondary adrenal suppression related to antiemetic dexamethasone therapy in cancer patients receiving chemotherapy. METHODS: Chemotherapy-naïve patients who were scheduled to receive at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Patients with a suppressed adrenal response before chemotherapy or those administered corticosteroids within 6 months of enrollment in the study were excluded. RESULTS: Between October 2010 and August 2014, 481 patients receiving chemotherapy underwent the rapid adrenocorticotropic hormone (ACTH) stimulation test to assess eligibility; 350 of these patients were included in the final analysis. Fifty-six patients (16.0%) showed a suppressed adrenal response in the rapid ACTH stimulation test at 3 or 6 months after the start of the first chemotherapy. The incidence of adrenal suppression was affected by age, performance status, stage, and use of megestrol acetate in univariate analysis. Multivariate analysis revealed that secondary adrenal suppression associated with antiemetic dexamethasone therapy was significantly associated with megestrol acetate treatment (odds ratio: 3.06; 95% confidence interval: 1.60 to 5.86; p < .001). CONCLUSION: This large prospective study indicates that approximately 15% of cancer patients receiving chemotherapy with a normal adrenal response show suppressed adrenal responses after antiemetic dexamethasone therapy. This result was particularly significant for patients cotreated with megestrol acetate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-acting glucocorticoids such as dexamethasone or betamethasone, even in physiologic daily dose equivalent, are more likely to cause HPA axis suppression, exogenous Cushing syndrome, and glucocorticoid withdrawal syndrome when being tapered (24, 74-78).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrison's principles of internal medicine
(2008) · Choice Reviews Online · doi:10.5860/choice.46-0330 · Cited by 3,083
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Harrison's Principles of Internal Medicine.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-167_1 · Cited by 1,523
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Chemotherapy-Induced Nausea and Vomiting
Hesketh, P. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706547 · Cited by 827
Arlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Clinical Trials : A Methodologic Perspective
Piantadosi, S. (1997) · Cited by 803
Oelkers, W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351607 · Cited by 737
Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Corticosteroid Therapy in Severe Illness
Lamberts, S. W. J., Bruining, H. A., & de Jong, F. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710303371807 · Cited by 488
Research works printed but not linked: 1
- 2015, NCCN Clinical Practice Guidelines in Oncology. Antiemesis, version 2, 2014
Cited by
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Jeong, Y., Han, H. S., Lee, H. D., Yang, J., Jeong, J., Choi, M. K., Kwon, J., Jeon, H., Oh, T., Lee, K. H., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.464 · Cited by 81
Self-citation
Metadata
- Authors
- Han, H. S., Park, J. C., Park, S. Y., Lee, K. T., Bae, S. B., Kim, H. J., Kim, S., Yun, H. J., Bae, W. K., Shim, H.-J., Hwang, J.-E., Cho, S.-H., Park, M.-R., Shim, H., Kwon, J., Choi, M. K., Kim, S. T., & Lee, K. H.
- Affiliations
- Chungbuk National University (KR)
- The Catholic University of Korea Daejeon St. Mary's Hospital (KR)
- Soonchunhyang University (KR)
- Chungnam National University (KR)
- Chonnam National University (KR)
- Wonkwang University (KR)
- Corresponding author
- Lee, Ki Hyeong
- ORCID
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-13
- Volume
- 20
- Issue
- 12
- Pages
- 1432-1439
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC4679085
- OpenAlex
- W2215816454
- Cited by
- 34
- References
- 32
- Citations by year
- 2026: 3 · 2024: 8 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 1
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- dexamethasone, antiemetic therapy, chemotherapy-induced nausea and vomiting, megestrol acetate, ACTH stimulation test, emetogenic chemotherapy, cancer patients, risk factors
- MeSH terms
- Adrenal Insufficiency, Adult, Aged, Aged, 80 and over, Antiemetics, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Hydrocortisone, Male, Middle Aged, Neoplasms, Prednisolone, Prospective Studies, Treatment Outcome, Megestrol Acetate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study. https://app.cochat.ai/papers/10.1634/theoncologist.2015-0211
- The paper
- Han, H. S., Park, J. C., Park, S. Y., Lee, K. T., Bae, S. B., Kim, H. J., Kim, S., Yun, H. J., Bae, W. K., Shim, H.-J., Hwang, J.-E., Cho, S.-H., Park, M.-R., Shim, H., Kwon, J., Choi, M. K., Kim, S. T., & Lee, K. H. (2015). A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study. The Oncologist. https://doi.org/10.1634/theoncologist.2015-0211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.